Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
MESOPOTAMIA, Ohio, April 19, 2016 -- An article in the Sunday Review section of the January 17 issue of The New York Times ("How Measurement Fails Doctors and Teachers") described the current fervor regarding outcomes measurement and accountability as possibly jeopardizing the quality of health care and education in the United States. However, the Times states, "We need more targeted measures, ones that have been vetted to ensure they really matter."
"At Hopewell, that vetting process is paramount," said Karges, Executive Director/CEO of Hopewell. "Since 2006, Hopewell has gathered and accessed data regarding the effectiveness of its programs and their impact on the recovery of its residents."
Hopewell's Outcomes Measurement Team is led by Candace Carlton, LISW-S, Quality Improvement and Compliance Director, and Sherry Bacon-Graves, BA, Outcomes Coordinator. The team also includes Sana Loue, PhD, MSSA, MA, JD, Hopewell's Research Consultant from Case Western Reserve University. Dr. Loue meets regularly with Carlton and Bacon-Graves, providing training on research techniques and the most effective methods of data analysis.
This team works with the Research Committee of Hopewell's board of directors to gather, analyze and report the periodic systematic measurements of each resident's progress as well as the effectiveness of each of Hopewell's programs as evidenced by the residents' progress, according to Karges. Over 70% of Hopewell residents have moved successfully into more self-reliant settings.
"Our outcomes measurement results show clearly that the Hopewell Model of care is effective," Karges continued. "The results lead us to improvement and may lead to programmatic changes. Often, the results indicate the need to replace older measurement tools with newer ones or to create customized tools as new programs are developed."
For more information about Hopewell's outcomes measurement and research, and to read the outcomes report, visit www.hopewellcommunity.org/files/news/2013outcomesreportrevised.pdf.
About Hopewell
Hopewell is a 300-acre residential working farm located in Mesopotamia, Ohio, where adults with schizophrenia, bipolar disorder and major depression learn to manage their mental illness and return to independent life. Hopewell is the only therapeutic farm community in Ohio. It is ODMHAS-licensed and CARF-accredited. Hopewell is a member of the National Alliance on Mental Illness and the American Residential Treatment Association.
Information and assessments are available by contacting Daniel Horne, director of admissions, at 440.426.2009. Visit www.hopewellcommunity.org.
CONTACT: Ed Stevens
440.617.0100 ext. 201
[email protected]
